• Imaging agents

Neuraceq Generic Name & Formulations

General Description

Florbetaben F 18 (50–5000MBq/mL [1.4–135mCi/mL] at End of Synthesis [EOS]); soln for IV inj.

Pharmacological Class

Radioactive diagnostic agent.

How Supplied

Multi-dose vial—50mL

Generic Availability


Mechanism of Action

Florbetaben F 18 is a F18-labeled stilbene derivative, which binds to ß-amyloid plaques in the brain. 

Neuraceq Indications


For positron emission tomography (PET) imaging of the brain to estimate ß-amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. 

Limitations of Use

A positive scan does not establish AD diagnosis or any other cognitive disorder. Safety and efficacy not established for predicting development of dementia or other neurologic conditions; or monitoring response to therapies. 

Neuraceq Dosage and Administration


Give as slow IV bolus at a rate of 6secs/mL into large vein in the arm. 300 MBq (8.1mCi), max 30mcg mass dose, in a total volume of up to 10mL. Follow with saline flush of ~10mL. Acquire PET images over 15–20mins starting 45–130mins after inj. 


Not indicated.

Neuraceq Contraindications

Not Applicable

Neuraceq Boxed Warnings

Not Applicable

Neuraceq Warnings/Precautions


Risk for radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk for image misinterpretation and other errors. Pregnancy. Nursing mothers: pump and discard breast milk for 24hrs post-inj. 

Neuraceq Pharmacokinetics


Plasma protein bound: 98.5%. 


Hepatic (CYP2J2, CYP4F2). 


Renal. Half-life: ~1hr. 

Neuraceq Interactions

Not Applicable

Neuraceq Adverse Reactions

Adverse Reactions

Inj site reactions (erythema, irritation, pain). 

Neuraceq Clinical Trials

See Literature

Neuraceq Note

Not Applicable

Neuraceq Patient Counseling

See Literature